|1.||Neoplasm Metastasis (Metastasis)
|5.||Stomach Neoplasms (Stomach Cancer)
|1.||Fan, Daiming: 124 articles (05/2015 - 01/2002)|
|2.||Noh, Sung Hoon: 122 articles (01/2016 - 01/2002)|
|3.||Hirakawa, Kosei: 93 articles (09/2015 - 12/2002)|
|4.||Hyung, Woo Jin: 92 articles (01/2016 - 01/2002)|
|5.||Yang, Han-Kwang: 90 articles (01/2016 - 01/2002)|
|6.||Kim, Woo Ho: 86 articles (01/2016 - 01/2002)|
|7.||Yoshikawa, Takaki: 83 articles (01/2016 - 01/2002)|
|8.||Mori, Masaki: 83 articles (10/2015 - 11/2002)|
|9.||Bang, Yung-Jue: 72 articles (11/2015 - 04/2002)|
|10.||Tsuburaya, Akira: 72 articles (10/2015 - 01/2002)|
|1.||Fluorouracil (Carac)FDA LinkGeneric
05/01/2003 - "Based on its remarkable effectiveness, marked improvement in the quality of life of the patients, and the convenience of its administration, the I/low-P regimen is recommended as a promising second-line chemotherapeutic regimen for patients with metastatic gastric cancer resistant to 5-FU."
09/01/1989 - "The fact that MMC, ADM, and 5-Fu are most effective in the treatment of gastric cancer suggests that the cell line MGc 80-3 may still retain its original drug sensitivity which is consistent with that noted in clinical gastric cancer. "
07/01/2015 - "S-1, a novel oral fluorouracil, has showed very effective in metastatic gastric cancer and became the standard option for gastric cancer with D2 dissection. "
12/01/2014 - "The efficacy of 5-fluorouracil (5-FU), an important chemotherapeutic agent for advanced gastric cancer (GC), is limited by 5-FU resistance. "
04/01/1992 - "However, in gastric cancer, 5-FU/FA and 5-FU/IFN seem to induce higher complete and overall remission rates in advanced gastric cancer compared with 5-FU alone. "
|2.||Cisplatin (Platino)FDA LinkGeneric
01/01/2005 - "Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. "
01/01/2010 - "A phase III trial of S-1 plus cisplatin (SP) versus S-1 alone, for first-line treatment of advanced gastric cancer (SPIRITS trial), has shown that overall survival was better in patients treated with SP than with S-1 alone. "
12/01/2007 - "We conducted a Phase I study to evaluate the safety and efficacy of a combination of S-1 with semi-weekly low-dose cisplatin in patients with unresectable/recurrent gastric cancer to determine the recommended dose (RD) for a subsequent Phase II study. "
08/01/2015 - "In summary, we have shown that S-1 combined with cisplatin is more effective, with acceptable toxicity in comparison with cisplatin alone in Chinese patients with advanced gastric cancer. "
04/01/2008 - "To define the maximum-tolerated dose (MTD) of S-1, given daily for 2 weeks followed by a 1-week rest, with a fixed dose of cisplatin on the initial day, and to determine the activity and safety of this regimen at the recommended dose (RD) when used as first line treatment of advanced gastric cancer (AGC). "
|3.||Paclitaxel (Taxol)FDA LinkGeneric
10/01/2004 - "[A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally]."
03/01/2006 - "Paclitaxel in combination with 5-FU/LV is clinically beneficial for patients with advanced gastric cancer and is a feasible salvage regimen for 5-FU-refractory gastric cancer patients."
12/01/2005 - "Phase II trials show that taxol is effective in treating advanced gastric cancer. "
04/01/2015 - "Our findings suggest that DIM enhances the therapeutic efficacy of paclitaxel in gastric cancer and is a potential clinical anticancer agent for the prevention and/or treatment of gastric cancer. "
02/01/2015 - "The paclitaxel-based regimens appeared to be effective in patients with advanced gastric cancer. "
|4.||docetaxel (Taxotere)FDA Link
02/01/2014 - "As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. "
02/01/2014 - "The combination of docetaxel and S-1 (DS) therapy is effective in patients with unresectable gastric cancer and is expected to be a regimen in neoadjuvant setting for advanced gastric cancer. "
01/01/2013 - "Therefore, Plu-CLA is a potential intraperitoneal-route carrier for hydrophobic docetaxel for the effective treatment of peritoneal metastatic gastric cancer."
01/01/2005 - "The combination of docetaxel and capectabine was found to be well tolerated and effective in patients with advanced gastric cancer. "
04/01/2012 - "Our study, for the first time, rationally demonstrated that LDM docetaxel treatment used alone or combined with EGCG is effective and safe in preclinical settings of gastric cancer. "
|5.||titanium silicide (TS-1)IBA
09/01/2006 - "This shows that TS-1 and CDDP may have potent therapeutic efficacy in advanced gastric cancer patients. "
05/01/2002 - "The current case suggests that TS-1 may have a potent therapeutic efficacy in cases of advanced gastric cancer."
01/01/2001 - "The current case suggests that TS-1 may have a potent therapeutic efficacy in advanced gastric cancer patients."
05/01/2005 - "Combination of TXL and TS-1 is expected to show good therapeutic efficacy and improve patients' QOL in patients with gastric cancer associated with peritoneal dissemination."
12/01/2003 - "Concurrent chemoradiation is feasible and seems to offer good results for recurrent gastric cancers resistant to TS-1."
|6.||trastuzumab (Herceptin)FDA Link
02/01/2015 - "Here, we describe the development of 1E11, a HER2-targeted humanized monoclonal antibody showing increased efficacy in a highly synergistic manner in combination with trastuzumab in the HER2-overexpressing gastric cancer cell lines NCI-N87 and OE-19. "
12/01/2011 - "In a recent trial (Trastuzumab for GAstric cancer), patients assigned to the trastuzumab treatment protocol showed an improved overall survival over those not receiving treatment. "
04/01/2011 - "The recent ToGA trial results indicated that trastuzumab is a new, effective, and well-tolerated treatment for HER2-positive gastric cancer (GC). "
10/14/2014 - "However, trastuzumab is effective for only 10% to 20% of the population with gastric cancer that expresses HER2 protein. "
09/01/2014 - "S-1/CDDP plus trastuzumab therapy as NAC for HER2-positive, advanced gastric cancer appears to be an effective treatment."
|7.||oxaliplatin (Eloxatin)FDA LinkGeneric
06/01/2010 - "In conclusion, patients with at least one (105)Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer."
11/01/2012 - "The combination of oxaliplatin and S-1 is effective in patients with advanced gastric cancer. "
09/01/2007 - "Oxaliplatin was reportedly effective for metastatic gastric cancer, but it is still non-approved in Japan. "
08/02/2004 - "This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer. "
05/01/2010 - "These findings indicate that SOX regimen with oxaliplatin at a dose of 100 mg/m(2) is feasible and shows promising efficacy against advanced gastric cancer."
|8.||capecitabine (Xeloda)FDA Link
05/01/2013 - "In practice, when oral therapy is preferred for a patient with advanced gastric cancer, capecitabine is still the best option because it carries a lower risk of serious gastrointestinal adverse effects."
11/01/2014 - "The present case suggests that capecitabine/CDDP therapy may be an effective treatment for S-1 pretreated patients with advanced or metastatic gastric cancer."
10/01/2012 - "S-1 and capecitabine are orally administered fluoropyridines reported to be effective in the treatment of advanced gastric cancer(AGC). "
01/01/2003 - "Capecitabine was suggested to be safe and effective in the treatment of advanced or recurrent gastric cancer. "
03/01/2009 - "Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. "
|9.||irinotecan (Camptosar)FDA LinkGeneric
06/01/2007 - "CPT-11 appeared to be highly efficacious when given in combination with CDDP in human gastric cancer cell lines. "
03/01/2011 - "Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment."
01/15/2013 - "Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials."
12/01/2007 - "The combination of 5-FU/LV and irinotecan as first-line treatment was found to be well tolerated and effective in patients with advanced gastric cancer. "
09/01/2005 - "S-1 with CPT-11 can be combined safely without CPT-11 effect on S-1 PK data and holds promise as an effective regimen for advanced gastric cancer."
|10.||Leucovorin (Folinic Acid)FDA Link
01/01/2011 - "The aim of this study was to evaluate the efficacy and safety of the modified FOLFOX-4 using low dose leucovorin for patients with advanced gastric cancer and analyze the efficacy of this regimen as first-line and salvage treatment. "
01/01/1996 - "Our results suggest that orally administered low-dose leucovorin can add to the efficacy of UFT in patients with gastric cancer, and provide preliminary data for a randomized clinical trial."
08/01/2005 - "A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer."
07/01/2009 - "Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients."
05/01/2007 - "As the tested regimen was generally safe and well tolerated by the patients, MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen for patients with advanced gastric cancer."
|1.||Drug Therapy (Chemotherapy)
11/01/2007 - "Since the routine introduction of chemotherapy for advanced gastric cancer in the early 1990 s, median survival for gastric cancer has improved from 3 months, with best supportive care alone, to > 11 months in recently reported Phase III trials of triplet chemotherapy. "
11/01/2013 - "For patients with advanced gastric cancer (AGC), chemotherapy has been found to improve survival and quality of life compared to best supportive care alone. "
08/01/2011 - "This analysis suggests that some clinicopathologic factors might be helpful in identifying the subgroup of patients most likely to benefit from third-line chemotherapy for advanced gastric cancer."
09/01/2007 - "However, chemotherapy alone can not cure patients with advanced gastric cancer that was shown to improve median survival time (MST), compared with patients provided with the best supportive care (BSC). "
01/01/2006 - "Currently, chemotherapy is the most effective treatment for outspread gastric cancer. "
11/01/2014 - "This retrograde intraduodenal drainage technique was safe and effective, and may be considered as an optimal treatment strategy for severe duodenum-related complications of gastrectomy for gastric cancer. "
01/01/2014 - "Regardless of whether patients underwent a one-stage or two-stage gastrectomy, curative R0 resection improved survival in patients with perforated gastric cancer. "
04/01/2010 - "The short-term outcome of laparoscopy-assisted distal gastrectomy for patients with early gastric cancer is superior to the open procedure, but its long-term outcome should be proven by further outcomes of RCTs."
01/01/2010 - "We retrospectively evaluated the effect of adjuvant S-1 on survival following recurrence and efficacy of first-line treatment in patients with recurrent gastric cancer after curative gastrectomy. "
07/01/2008 - "In advanced gastric cancer patients with non-curative factors, gastrectomy was beneficial for survival with longer maintenance of oral intake."
|3.||Combination Drug Therapy (Combination Chemotherapy)
12/01/2013 - "Recent studies have shown that combination chemotherapy of fluoropyrimidine and EGFR-targeting agents is effective for gastric cancer patients highly expressing EGFR. "
05/01/2008 - "The S-1/PTX combination chemotherapy was thought to be effective for gastric cancer with peritoneal dissemination and made curative operation possible in this case."
01/01/2007 - "The modified FOLFOXIRI combination chemotherapy showed a very promising preliminary antitumor activity and was generally well tolerated as a first-line treatment of patients with metastatic gastric cancer."
07/01/1992 - "This study suggests that oral UFT as a maintenance treatment may be beneficial in the combination chemotherapy for human gastric cancer."
07/01/2009 - "[A case of nonresected gastric cancer with peritoneal dissemination effectively treated by S-1/DOC and PTX/ CDDP combination chemotherapy with good QOL]."
|4.||Lymph Node Excision (Lymph Node Dissection)
03/01/2011 - "Surgery is the only curative strategy for gastric cancer management and radical resection with free margins and extended lymphadenectomy seems to be the best option. "
01/01/2007 - "The best results in the surgical treatment of gastric cancer are those obtained by the Japanese surgical school that emphasizes D2 lymphadenectomy as a fundamental principle for obtaining better local control of the disease. "
01/01/2002 - "The most effective treatment for gastric cancer is complete surgical resection with lymphadenectomy. "
10/01/1992 - "These findings suggest that in Britain in the 1990s, as in Japan, it may be possible to diagnose an increasing proportion of patients with gastric cancer at a relatively early pathological stage, when most patients can be cured by radical surgical resection with lymphadenectomy."
08/01/2009 - "The only treatment modality showing improved survival for gastric cancer is curative surgical resection, which comprises the resection of stomach, proper lymphadenectomy, and reconstruction. "
11/01/2012 - "Thus, research efforts should focus on which regimens are the most effective for patients with recurrent gastric cancer after combined treatment with surgery and perioperative or adjuvant chemotherapy. "
05/01/2012 - "The peritoneum is still the most frequent site of recurrence in stage II/III gastric cancer patients, although the survival rate was improved by the introduction of S-1 adjuvant chemotherapy. "
11/01/2000 - "Furthermore, the efficacy of adjuvant chemotherapy after curative resection for gastric cancer was warranted by a meta-analysis of 19 published randomized trials. "
07/01/2000 - "Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. "
08/01/2008 - "The efficacy of adjuvant chemotherapy using S-1 for one year after curative surgical treatment for patients with gastric cancer of stage II or III was reported as the result of randomized controlled trial named ACTS-GC in 2007. "